Health-related quality of life data from a phase 3, international, randomized, open-label, multicenter study in patients with previously treated mantle cell lymphoma treated with ibrutinib versus temsirolimus

Mantle cell lymphoma (MCL) is a rare, aggressive, incurable B-cell malignancy. Ibrutinib has been shown to be highly active for patients with relapsed/refractory (R/R) MCL. The RAY trial (MCL3001) was a phase 3, randomized, open-label, multicenter study that compared ibrutinib with temsirolimus in patients with R/R MCL. Active disease is frequently associated with impaired functional status and reduced well-being. Therefore, the current study employed two patient-reported outcome instruments, the Functional Assessment of Cancer Therapy-Lymphoma (FACT-Lym) and the EQ-5D-5L, to assess symptoms, well-being, health status, and health-related quality of life of patients on treatment within the RAY trial. We found that patients on ibrutinib had substantial improvement in FACT-Lym subscale and total scores, and had improvement in EQ-5D-5L utility and VAS scores compared with temsirolimus patients, indicating a superior well-being. These improvements in well-being correlated with clinical response, indicating that better health-related quality of life was associated with decreased disease burden.

Rule, SimonPlymouth University (författare)
Jurczak, WojciechJagiellonian University (författare)
Jerkeman, MatsLund University,Lunds universitet,Tumörmikromiljö,Sektion I,Institutionen för kliniska vetenskaper, Lund,Medicinska fakulteten,Tumor microenvironment,Section I,Department of Clinical Sciences, Lund,Faculty of Medicine,Skåne University Hospital(Swepub:lu)onk-mje (författare)
Santucci Silva, RodrigoInstituto de Ensino e Pesquisa do Hospital São Lucas (författare)
Rusconi, ChiaraNiguarda Hospital (författare)
Caballero, DoloresUniversity Hospital of Salamanca (författare)
Joao, CristinaChampalimaud Foundation (författare)
Witzens-Harig, MathiasUniversity Hospital Heidelberg (författare)
Bence-Bruckler, Isabelle (författare)
Cho, Seok-Goo (författare)
Zhou, WenjiongJanssen Pharmaceuticals, US (författare)
Goldberg, Jenna DJanssen Pharmaceuticals, US (författare)
Trambitas, CristinaJanssen Inc., Canada (författare)
Enny, ChristopherJanssen Pharmaceuticals, US (författare)
Vermeulen, JessicaJanssen Pharmaceuticals, US (författare)
Traina, ShanaJanssen Pharmaceuticals, US (författare)
Chiou, Chiun FangJanssen Pharmaceuticals, US (författare)
Diels, JorisJanssen Pharmaceutica (författare)
Dreyling, MartinUniversity Hospital Munich (författare)
Johannes-Gutenberg University MainzPlymouth University (creator_code:org_t)

Ingår i:Leukemia and Lymphoma: Informa UK Limited58:12, s. 2824-28321042-81941029-2403

Om ämnet

MEDICIN OCH HÄLSOVETENSKAP: MEDICIN OCH HÄLS ...; och Klinisk medicin; och Cancer och onkol ...

Kungliga biblioteket hanterar dina personuppgifter i enlighet med EU:s dataskyddsförordning (2018), GDPR. Läs mer om hur det funkar här.
Så här hanterar KB dina uppgifter vid användning av denna tjänst.